Patients with the most advanced rheumatoid arthritis remain with Th1 systemic defects after TNF inhibitors treatment despite clinical improvement

Rheumatology International

Volumn 34, Issue 2, 2014, Pages 243-253

  Kosmaczewska, Agata ^a   Swierkot, Jerzy ^b   Ciszak, Lidia ^a   Szteblich, Aleksandra ^a   Chrobak, Agnieszka ^a   Karabon, Lidia ^a   Partyka, Anna ^a   Szechinski, Jacek ^b   Wiland, Piotr ^b   Frydecka, Irena ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Cytokines; MTX; Rheumatoid arthritis; Th1 Th17 Treg imbalance; TNF inhibitors

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 6; MESSENGER RNA; METHOTREXATE; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE DURATION; DOWN REGULATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFLAMMATION; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; TH1 CELL; TH17 CELL; YOUNG ADULT;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; FLOW CYTOMETRY; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84895789587     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-013-2895-9     Document Type: Article

References (62)

1. Weyand CM, Goronzy JJ (1997) Pathogenesis of rheumatoid arthritis. Med Clin N Am 81:29-55
2. Toh ML, Miossec P (2007) The role of T cells in rheumatoid arthritis: new subsets and new targets. Curr Opin Rheumatol 19:284-288
3. Afzali B, Lombardi G, Lechler RI, Lord GM (2007) The role of T helper transplantation and autoimmune disease. Clin Exp Immunol 148:32-46
4. Kelchtermans H, De Klerck B, Mitera T, et al. (2005) Defective CD4+CD25+ regulatory T cell functioning in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-gamma. Arthritis Res Ther 7:R402-R415
5. Setoguchi R, Hori S, Takahashi T, Sakaguchi S (2005) Homeostatic maintenance of natural Foxp3+CD25+CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201:723-735
6. Rosloniec EF, Latham K, Guedez Y (2002) Paradoxical roles of IFN-gamma in models of Th1-mediated autoimmunity. Arthritis Res 4:333-336
7. Arnett FC, Edworthy SM, Bloch DA, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
8. Smolen JS, Landewe R, Breedveld FC, et al. (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964-975
9. Hennessy B, North J, Deru A, Llewellyn-Smith N, Lowdell MW (2001) Use of Leu3a/3b for the accurate determination of CD4 subsets for measurement of intracellular cytokines. Cytometry 44:148-152
10. Nitsch SM, Pries R, Wollenberg B (2007) Head and neck cancer triggers increased IL-6 production of CD34+ stem cell from human cord blood. In vivo 21:493-498
11. Niu Q, Cai B, Huang ZC, Shi YY, Wang LL (2012) Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatol Int 32:2731-2736
12. Wang W, Shao S, Jiao Z, Guo M, Xu H, Wang S (2012) The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis. Rheumatol Int 32:887-893
13. Shen H, Xia L, Lu J, Xiao W (2010) Infliximab reduces the frequency of interleukin 17-producing cells and the amounts of interleukin 17 in patients with rheumatoid arthritis. J Investig Med 58:905-908
14. Yue C, You X, Zhao L, et al. (2010) The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Rheumatol Int 30:1553-1557
15. Lina C, Conghua W, Nan L, Ping Z (2011) Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis. J Clin Immunol 31:596-605
16. Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL (2001) Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-alpha therapy. Arthritis Res Ther 13:R126
17. Chen J, Li J, Gao H, et al. (2012) Comprehensive evaluation of different T-helper cell subsets differentiation and function in rheumatoid arthritis. J Biomed Biotechnol 2012:535361
18. Alzabin S, Abraham SM, Taher TE, et al. (2012) Incomplete response of inflammatory arthritis to TNF-alpha blockade is associated with the Th17 pathway. Ann Rheum Dis 71:1741-1748
19. McGovern JL, Nguyen DX, Notley CA, Mauri C, Isenberg DA, Ehrenstein MR (2012) Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis Rheum 64:3129-3138
20. Szalay B, Vasarhelyi B, Cseh A, et al. (2013) The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study. Clin Rheumatol. doi: 10.1007/s10067-013-2352-x
21. Van Hamburg JP, Asmawidjaja PS, Davelaar N, et al. (2011) Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum 63:73-83
22. Bettelli E, Oukka M, Kuchroo VK (2007) T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 8:345-350
23. Miossec P (2007) Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified. Arthritis Rheum 56:2111-2115
24. Van Bezooijen RL, Van Der Wee-Pals L, Papapoulos SE, Lowik CW (2002) Interleukin 17 synergizes with tumor necrosis factor alpha to induce cartilage destruction in vitro. Ann Rheum Dis 61:870-876
25. Moran EM, Mullan R, McCormick J, et al. (2009) Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumor necrosis factor-alpha, oncostatin M and response to biologic therapies. Arthritis Res Ther 11:R113
26. Sato K, Suenatsu A, Okamoto K, et al. (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203:2673-2682
27. Acosta-Rodrigez EV, Rivino L, Geginat J, et al. (2007) Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 8:639-646
28. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J (1988) Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 31:784-788
29. Knudsen LS, Hetland ML, Johansen JS, et al. (2009) Changes in plasma IL-6, plasma VEGF and serum YKL-40 during treatment with etanercept and methotrexate or etanercept alone in patients with active rheumatoid arthritis despite methotrexate therapy. Biomark Insights 4:91-95
30. Hussein MR, Fathi NA, El-Din AME, et al. (2008) Alterations of the CD4+, CD8+ T cell subsets, interleukins-1β, IL-10, IL-17, tumor necrosis factor-α and soluble intercellular adhesion molecule-1 in rheumatoid arthritis and osteoarthritis: preliminary observations. Pathol Oncol Res 14:321-328
31. Macias I, Garcia-Perez S, Ruiz-Tudela M, et al. (2005) Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-alpha blockade in patients with rheumatoid arthritis. J Rheumatol 32:2102-2108
32. Meyer PWA, Hodkinson B, Ally M, et al. (2010) Circulating cytokine profiles and their relationships with autoantibodies, acute phase reactants, and disease activity in patients with rheumatoid arthritis. Mediators Inflamm 2010:158514
33. Marti L, Golmia R, Golmia APF, et al. (2009) Alterations in cytokine profile and dendritic cell subsets in peripheral blood of rheumatoid arthritis patients before and after biologic therapy. Ann NY Acad Sci 1173:334-342
34. Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik B, Skowronski J, Chwiecko J (2001) Serum cytokines of different histological variants of rheumatoid arthritis. J Rheumatol 28:1211-1217
35. Tukaj S, Kotlarz A, Jozwik A, et al. (2010) Cytokines of the Th1 and Th2 type in sera of rheumatoid arthritis patients; correlations with anti-Hsp40 immune response and diagnostics markers. Acta Biochim Pol 57:327-332
36. De Paz B, Alperi-Lopez M, Ballina-Garcia FJ, Prado C, Gutierrez C, Suarez A (2010) Cytokines and regulatory T cells in rheumatoid arthritis and their relationship with response to corticosteroids. J Rheumatol 37:2502-2510
37. Lawson CA, Brown AK, Bejarano V, et al. (2006) Early rheumatoid arthritis is associated with a deficit in the CD4+CD25 high regulatory T cell population in peripheral blood. Rheumatology (Oxford) 45:1210-1217
38. Ehrenstein MR, Evans JG, Singh A, et al. (2004) Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF-alpha therapy. J Exp Med 200:277-285
39. Han GM, O'Neil-Andersen NJ, Zurier RB, Lawrence DA (2008) CD4+CD25high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis. Cell Immunol 253:92-101
40. Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR (2008) Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci USA 105:19396-19401
41. Kawashima M, Miossec P (2005) mRNA quantification of T-bet, GATA-3, IFN-gamma, and IL-4 shows a defective Th1 immune response in the peripheral blood from rheumatoid arthritis patients: link with disease activity. J Clin Immunol 25:209-214
42. van Roon JAG, Verhoef CM, van Roy JLAM, et al. (1997) Decrease in peripheral type 1 over type 2 T cell cytokine production in patients with rheumatoid arthritis correlates with an increase in severity of disease. Ann Rheum Dis 56:656-660
43. Berner B, Akca D, Jung T, Muller GA, Reuss-Borst MA (2000) Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry. J Rheumatol 27:1128-1135
44. Samson M, Audia S, Janikashvili N, et al. (2012) Inhibition of IL-6 function corrects Th17/Treg imbalance in rheumatoid arthritis patients. Arthritis Rheum 64:2499-2503
45. Toh ML, Kawashima M, Hot A, Miossec P, Miossec P (2007) Role of IL-17 in the Th1 systemic defects in rheumatoid arthritis through selective IL-12Rbeta2 inhibition. Ann Rheum Dis 69:1562-1567
46. Diehl S, Anguita J, Hoffmeyer A, et al. (2000) Inhibition of Th1 differentiation by IL-6 is mediated by SOCS 1. Immunity 13:805-815
47. van der Graaf WL, Prins APA, Niers TMH, Dijkmans BA, van Lier RA (1999) Quantification of interferon gamma- and interleukin-4-producing T cells in synovial fluid and peripheral blood of arthritis patients. Rheumatology 38:214-220
48. Yamada H, Nakashima Y, Okazaki K, et al. (2008) Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Ann Rheum Dis 67:1299-1304
49. Xinqiang S, Fei L, Nan L, et al. (2010) Therapeutic efficacy of experimental rheumatoid arthritis with low-dose methotrexate by increasing partially CD4+CD25+ Treg cells and inducing Th1 to Th2 shift in both cells and cytokines. Biomed Pharmacother 64:463-471
50. Schotte H, Schlutter B, Willeke P, et al. (2004) Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology 43:960-964
51. Blaschke S, Viereck V, Schwarz G, Klinger HM, Guerluek S, Muller GA (2009) Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis. Scand J Rheumatol 38:235-239
52. Cope AP, Londei M, Chu NR, et al. (1994) Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 94:749-760
53. Avramescu C, Vere CC, Margaritescu C, et al. (2005) Cytokine panel in rheumatoid arthritis and correlation with histological patterns of synovitis - active type of disease. Rom J Morphol Embryol 46:87-92
54. Tang Q, Adams JY, Penaranda C, et al. (2008) Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28:687-697
55. Nadkarni S, Mauri C, Ehrenstein MR (2007) Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 204:33-39
56. loFoxP3+CD4+ T cells with limited suppressor activity. Eur J Immunol 41:1480-1490
57. Laurence A, Tato CM, Davidson TS, et al. (2007) Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26:371-381
58. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM (2004) IL-2 is critically required for the in vitro activation of CD4+CD256+ T cell suppressor function. J Immunol 172:6519-6523
59. Keane J, Gershon S, Wise RP, et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098-1104
60. Malek TR, Yu A, Vincek V, Kong L (2002) CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17:167-178
61. Irmler IM, Gajda M, Brauer R (2007) Exacerbation of antigen-induced arthritis in IFN-gamma-deficient mice as a result of unrestricted IL-17 response. J Immunol 179:6228-6236
62. Perkins D, Wang Z, Donovan C, et al. (1996) Regulation of CTLA-4 expression during T cell activation. J Immunol 156:4154-4159